Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance.

Current opinion in pharmacology - 1 Feb 2022

Chakraborty Chiranjib, Bhattacharya Manojit, Sharma Ashish Ranjan

Abstract excerpt

Several clinical trials started during the COVID-19 pandemic to discover effective therapeutics led to identify a few candidates from the major clinical trials. However, in the past several months, quite a few SARS-CoV-2 variants have emerged with significant mutations. Major mutations in the S-glycoprotein and other parts of the genome have led to the antibody's escape to small molecule-based therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Monoclonal and Polyclonal Antibodies Research

Share to Mutation

Share to Pandemics

Share to SARS-CoV-2

Share to SARS-CoV-2 and COVID-19 Research

Share to Spike Glycoprotein, Coronavirus

Source

Open in PubMed Open full text

Identifiers

PMID: 34920267
DOI: 10.1016/j.coph.2021.11.006
PMCID: PMC8606259

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance.PMID 34920267Read ↗

Antibody drugs targeting SARS-CoV-2: Time for a rethink?Semantic proximity Read ↗

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19Semantic proximity Read ↗

The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies.Semantic proximity Read ↗

Overcoming Variants Resistance in Monoclonal Antibody for Antiviral TherapySemantic proximity Read ↗

Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies.Semantic proximity Read ↗

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.Semantic proximity Read ↗

Updated Atlas of Currently Available Human Neutralizing Antibodies Against SARS-CoV-2 and Escape by Omicron Sub-Variants BA.2.12.1/BA.2.13/BA.4/BA.5Semantic proximity Read ↗

Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escapeSemantic proximity Read ↗

Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3Semantic proximity Read ↗

REGEN-COV protects against viral escape in preclinical and human studiesSemantic proximity Read ↗

TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351)Semantic proximity Read ↗

Comprehensive Mapping of Binding Hot Spots of SARS-CoV-2 RBD-specific Neutralizing Antibodies for Tracking Immune Escape VariantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.